Q1 2025 Esperion Therapeutics Inc Earnings Call Transcript
Key Points
- Esperion Therapeutics Inc (ESPR) reported a 63% year-over-year growth in total revenue for Q1 2025, reaching $65 million after adjusting for a one-time milestone in Q1 2024.
- US net product revenue increased by 41% year-over-year to $34.9 million, driven by expanded label and commercial initiatives.
- The company expanded its field reimbursement support team threefold, enhancing payer access and support for prescribers.
- NEXLETOL and NEXLIZET were added to the 2025 ACC AHA multi-society guidelines, earning high-level recommendations for patients with acute coronary syndrome.
- Esperion Therapeutics Inc (ESPR) is advancing its pipeline with a novel program targeting primary sclerosing cholangitis (PSC), a major unmet need with a $1 billion annual market opportunity.
- Total revenue decreased by 53% compared to Q1 2024 due to a one-time settlement agreement milestone received in the previous year.
- The flat lipid market in the US and changes in Medicare Part D impacted Q1 2025 product revenue growth.
- Collaboration revenue decreased by 73% compared to Q1 2024, primarily due to the absence of the previous year's milestone.
- Esperion Therapeutics Inc (ESPR) faced seasonal headwinds with higher out-of-pocket costs for patients due to insurance deductible resets.
- The company experienced confusion and challenges related to the Inflation Reduction Act and Medicare adjustments, affecting prescription uptake.
Ladies and gentlemen, thank you for standing by, and welcome. (Operator Instructions)
Please be advised that today's conference call will be recorded. I would now like to hand the conference over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. Please go ahead.
Thank you, operator. Good morning, and welcome to Esperion's first-quarter 2025 earnings conference call. With us on today's call are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks. We issued a press release earlier this morning detailing the content of today's call.
A copy can be found on the Investor page of our website, together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
